ArticleCureus2026
Anti-Glutamic Acid Decarboxylase 65 (Anti-GAD65) Autoimmune Encephalopathy: A Case of Diagnostic and Treatment Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-glutamic acid decarboxylase 65 (anti-GAD65) autoimmune encephalopathy is an uncommon but increasingly recognized cause of cognitive impairment and refractory seizures. We report a 69-year-old woman with a background of insulin-treated diabetes mellitus, hypertension, hypercholesterolemia, and prior hyperthyroidism, who presented with acute altered consciousness and cognitive dysfunction. Initial investigations excluded metabolic, infectious, vascular, and paraneoplastic causes. Cerebrospinal fluid (CSF) analysis showed mildly elevated protein without pleocytosis, and MRI brain demonstrated nonspecific periventricular T2/FLAIR hyperintensities. Thyroid antibodies were markedly elevated, raising suspicion for Hashimoto's encephalopathy; however, an extended autoimmune panel revealed strongly positive anti-GAD65 antibodies (50.9 nmol/L; reference <0.02). She was treated with intravenous immunoglobulin and pulsed methylprednisolone, with partial improvement but persistent slow mentation. Rituximab was planned, but follow-up was lost. This case highlights the diagnostic overlap between anti-GAD65 encephalitis and Hashimoto's encephalitis, underscores the importance of comprehensive antibody testing in unexplained encephalopathy, and illustrates the incomplete response to first-line immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.